Ira Gupta Selected Research

belantamab mafodotin

4/2024	Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma.
12/2023	Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial.
11/2023	Safety, pharmacokinetics, and efficacy of belantamab mafodotin monotherapy in Japanese patients with relapsed or refractory multiple myeloma: DREAMM-11.
9/2023	Patient-Reported Outcomes With Belantamab Mafodotin Treatment in Patients With Triple-Class Refractory Multiple Myeloma.
11/2021	Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study.
1/2021	Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM).
1/2021	Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design.
12/2020	Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study.
12/2020	Correction to: Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study.
10/2020	Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ira Gupta Research Topics

Disease

13	Multiple Myeloma 04/2024 - 01/2019
3	Disease Progression 11/2023 - 01/2020
3	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2017 - 06/2011
2	Fatigue 09/2023 - 09/2016
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2019 - 01/2018
2	Neoplasms (Cancer) 01/2018 - 04/2012
2	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 05/2012 - 04/2012
1	Pain (Aches) 09/2023
1	Hematologic Neoplasms (Hematological Malignancy) 01/2019
1	Lymphadenopathy 01/2017
1	Neutropenia 10/2015
1	Infections 10/2015

Drug/Important Bio-Agent (IBA)

12	belantamab mafodotinIBA 04/2024 - 01/2019
7	ofatumumab FDA Link 01/2017 - 06/2011
6	Immunoconjugates (Immunoconjugate)IBA 11/2023 - 01/2019
4	B-Cell Maturation AntigenIBA 11/2023 - 01/2019
3	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2017 - 06/2011
3	fludarabineIBA 01/2017 - 06/2011
2	Immunomodulating AgentsIBA 11/2021 - 01/2020
2	Proteasome InhibitorsIBA 11/2021 - 01/2020
2	Monoclonal AntibodiesIBA 01/2020 - 05/2012
2	enasidenibIBA 01/2019 - 01/2018
1	pembrolizumabIBA 04/2024
1	Biomarkers (Surrogate Marker)IBA 10/2021
1	Amyloid Precursor Protein Secretases (beta-Secretase)IBA 01/2021
1	dostarlimabIBA 01/2021
1	nirogacestatIBA 01/2021
1	Arginine (L-Arginine)FDA Link 01/2019
1	isocitric acid (isocitrate)IBA 01/2019
1	Proteins (Proteins, Gene)FDA Link 01/2018
1	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 01/2018
1	Mesylates (Mesylate)IBA 01/2018
1	Thymidine KinaseIBA 01/2017
1	Chlorambucil (Leukeran)FDA Link 09/2016
1	Prednisone (Sone)FDA LinkGeneric 05/2012
1	Vincristine (Oncovin)FDA LinkGeneric 05/2012
1	Doxorubicin (Adriamycin)FDA LinkGeneric 05/2012
1	Rituximab (Mabthera)FDA Link 04/2012

Therapy/Procedure

6	Therapeutics 11/2021 - 06/2011
2	Intravenous Infusions 11/2023 - 01/2020
1	Drug Therapy (Chemotherapy) 04/2012